Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.39 |
| ▸ | WIZ | O95785 | 4/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982837 | 1.00 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CCRBNWIZ | |
| SCHEMBL23915685 | 0.83 | CRBN (0.46) | CRBNWIZDDB1 | |
| SCHEMBL21897714 | 0.81 | POLB (0.47) | CRBNDDB1 | |
| SCHEMBL21906782 | 0.80 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL25771919 | 0.78 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL24870630 | 0.78 | MAOA (0.40) | CRBNWIZDDB1 | |
| SCHEMBL24389203 | 0.78 | CRBN (0.41) | CRBNWIZDDB1 | |
| SCHEMBL29614648 | 0.78 | CRBN (0.61) | CRBNWIZ | |
| SCHEMBL20231317 | 0.78 | CRBN (0.61) | CRBNWIZ | |
| SCHEMBL20442557 | 0.78 | CRBN (0.61) | CRBNWIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267305-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | ADRA2A 3011/4885ADRA2B 3585/4885ADRA2C 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.